XML 48 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restatement (Tables)
12 Months Ended
Sep. 29, 2017
Accounting Changes And Error Corrections [Abstract]  
Summary of Significant Effect of Restatement

A summary of the effects of the Restatement for fiscal years 2017, 2016 and the 2015 transition period is as follows:

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Eleven Months Ended

 

 

In Thousands, Except Per Share Amounts

2017

 

 

2016

 

 

2015

 

 

 

(As Reported)

 

(Restated)

 

 

(As Reported)

 

(Restated)

 

 

(As Reported)

 

(Restated)

 

 

Consolidated Statement of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

$

2,002,195

 

$

2,000,304

 

 

$

1,992,631

 

$

1,993,453

 

 

$

1,774,449

 

$

1,774,449

 

 

Cost of Sales

 

1,336,736

 

 

1,340,259

 

 

 

1,331,386

 

 

1,331,573

 

 

 

1,185,056

 

 

1,186,606

 

 

Selling, general & administrative

 

375,413

 

 

374,981

 

 

 

395,274

 

 

396,548

 

 

 

346,781

 

 

348,766

 

 

Research, development and engineering

 

103,024

 

 

109,778

 

 

 

95,939

 

 

99,710

 

 

 

91,491

 

 

91,868

 

 

Operating Earnings from Continuing

   Operations

 

194,811

 

 

183,075

 

 

 

170,159

 

 

165,749

 

 

 

156,985

 

 

153,073

 

 

Income Tax Expense

 

38,928

 

 

33,025

 

 

 

22,535

 

 

21,857

 

 

 

18,956

 

 

16,486

 

 

Earnings from Continuing Operations

   Attributable to Esterline, Net of Tax

 

124,698

 

 

118,865

 

 

 

116,951

 

 

113,219

 

 

 

96,665

 

 

95,223

 

 

Net Earnings Attributable to Esterline

 

117,387

 

 

111,554

 

 

 

101,685

 

 

97,953

 

 

 

59,612

 

 

58,170

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings Per Share Attributable to Esterline - Basic:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

$

4.19

 

$

4.00

 

 

$

3.97

 

$

3.84

 

 

$

3.15

 

$

3.10

 

 

Earnings Per Share

$

3.94

 

$

3.75

 

 

$

3.45

 

$

3.32

 

 

$

1.94

 

$

1.89

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings Per Share Attributable to Esterline - Diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

$

4.15

 

$

3.96

 

 

$

3.93

 

$

3.80

 

 

$

3.10

 

$

3.05

 

 

Earnings Per Share

$

3.91

 

$

3.72

 

 

$

3.42

 

$

3.29

 

 

$

1.91

 

$

1.86

 

 

In the consolidated financial statements, the impact of the restatement in fiscal 2014 are reflected in this Amendment as an adjustment of $0.9 million to beginning retained earnings for fiscal 2015.

 

A summary of the effects of the Restatement as of September 29, 2017, September 30, 2016, and October 2, 2015, is as follows:

 

In Thousands

2017

 

 

2016

 

 

2015

 

 

 

(As Reported)

 

(Restated)

 

 

(As Reported)

 

(Restated)

 

 

(As Reported)

 

(Restated)

 

 

Consolidated Balance Sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

$

437,963

 

$

430,524

 

 

$

422,073

 

$

421,511

 

 

$

380,748

 

$

380,450

 

 

Inventories

 

482,701

 

 

477,969

 

 

 

450,206

 

 

447,095

 

 

 

446,768

 

 

442,315

 

 

Prepaid expenses

 

18,816

 

 

19,239

 

 

 

17,909

 

 

18,378

 

 

 

23,008

 

 

23,156

 

 

Deferred income tax benefits

 

55,355

 

 

56,793

 

 

 

75,409

 

 

75,790

 

 

 

28,979

 

 

27,982

 

 

Accounts payable

 

133,101

 

 

138,595

 

 

 

121,816

 

 

126,607

 

 

 

117,976

 

 

118,734

 

 

Accrued liabilities

 

229,610

 

 

230,007

 

 

 

238,163

 

 

235,649

 

 

 

259,734

 

 

256,147

 

 

U.S. and foreign income taxes

 

6,111

 

 

582

 

 

 

10,932

 

 

9,695

 

 

 

2,404

 

 

1,861

 

 

Other liabilities

 

17,658

 

 

18,838

 

 

 

21,968

 

 

23,026

 

 

 

29,367

 

 

30,174

 

 

Deferred income tax liabilities

 

43,978

 

 

43,978

 

 

 

53,798

 

 

54,325

 

 

 

73,849

 

 

73,106

 

 

Total Shareholders' Equity

 

1,847,128

 

 

1,835,276

 

 

 

1,611,131

 

 

1,605,865

 

 

 

1,547,791

 

 

1,545,496